Full-Time
Vice President Human Resources
Updated on 9/4/2026
Quantum-Si
51-200 employees
Proteomics instrument platform for NGPS sequencing
Compensation Overview
$250k - $275k/yr
No H1B Sponsorship
San Diego, CA, USA
Remote
Travel up to 25% of the time is required.
Bachelor's
 People & HR (1) |
|---|
Get referred to Quantum-Si
See people who can refer or advise you
- A bachelor's degree in Human Resources, Business Administration, Organizational Development, Psychology, or a related field is required.
- At least 10 years of progressive Human Resources experience, including significant leadership responsibility across multiple HR disciplines, is required.
- At least 7 years of experience leading HR teams in a fast-paced, growing, or complex organization is required.
- The candidate must be able to lead in a hands-on, collaborative manner while balancing strategic priorities with day-to-day execution.
- Demonstrated success partnering with executive leadership teams to align people strategies with business objectives is required.
- Experience leading core HR functions, including talent acquisition, total rewards, performance management, employee relations, organizational development, compliance, and HR operations, is required.
- Strong knowledge of federal and state employment laws and HR compliance requirements is required.
- Experience managing a global professional employer organization or employer of record and leading global HR programs while supporting international employees is required.
- Proven ability to lead organizational change, workforce planning, restructuring initiatives, and culture transformation efforts is required.
- Experience developing and implementing compensation, equity, and incentive programs is required.
- Strong analytical and business acumen, including the ability to leverage people metrics to inform decisions, is required.
- Ability to influence senior leaders and drive results through collaboration and accountability is required.
- Candidates must be authorized to work in the United States.
- Ability to travel up to 25% of the time is required.
- Develop and execute the company's global people strategy in support of business objectives and long-term growth.
- Serve as a trusted advisor to the CEO and executive leadership team on talent, organizational effectiveness, culture, succession planning, and workforce strategy.
- Provide strategic leadership and oversight of all Human Resources functions, including talent acquisition, payroll and benefits, HR operations, employee relations, performance management, learning and development, engagement, and compliance.
- Partner with business leaders to design organizational structures that enable scalability, efficiency, and achievement of strategic goals.
- Partner with the CEO and CFO to design and implement compensation, equity, and benefits programs that support competitive, equitable, and fiscally responsible rewards practices.
- Support Compensation Committee activities, including market benchmarking, plan design, and governance.
- Develop and implement talent management and succession planning processes to build leadership capability across the organization.
- Sponsor and champion performance management, leadership accountability, employee development, and recognition programs across the organization.
- Ensure compliance with employment laws and regulations in all jurisdictions where the company operates.
- Provide strategic guidance on complex employee relations matters, workplace investigations, risk management, and policy development efforts.
- Champion employee engagement, inclusion, and company culture initiatives that support attraction, retention, and productivity.
- Manage workforce planning, restructuring activities, change management initiatives, and organizational transformations.
- Establish HR metrics and analytics to guide decision-making and measure the effectiveness of people programs.
- Build, mentor, and develop a high-performing HR team while fostering operational excellence and continuous improvement.
- Oversee HR systems, processes, and controls to ensure efficient, scalable, and compliant operations.
- Prior experience in a start-up is helpful.
- Experience supporting a public company environment.
- Experience working with Compensation Committees and Board-level governance matters.
- Background in biotechnology, life sciences, med-tech, or healthcare.
- HR certification such as PHR, SPHR, SHRM-CP, or SHRM-SCP.
Quantum-Si provides proteomics tools that analyze proteins at the single-molecule level using NGPS on a semiconductor chip. The workflow immobilizes peptides on a chip, uses fluorescent recognizers to read amino acids as they are cleaved, and delivers data through an end-to-end platform of benchtop instruments, consumables, and cloud software. It differentiates itself by combining semiconductor-based single-molecule proteomics with an integrated, easy-to-use platform and flexible financing that converts capital expenditures to operating expenses. Its goal is to speed up drug discovery and clinical diagnostics by enabling detailed profiling of proteoforms and post-translational modifications across research, pharma, and diagnostics labs.
Company Size
51-200
Company Stage
IPO
Headquarters
Guilford, Connecticut
Founded
2013
Get referred to Quantum-Si
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 13, 2026 Q2 results extended cash runway to Q4 2028 after restructuring.
- Proteus launch slipped to Q2 2027, but early-access sites start this summer.
- Quantum-Si targeted 17 amino acids in April and 19 or 20 at launch.
What critics are saying
- July 23, 2026 Nasdaq notice starts a January 19, 2027 delisting clock.
- Revenue was $344,000 in Q2 2026, while management cut 20% of staff.
- Proteus delay to Q2 2027 proves manufacturing repeatability still blocks commercialization and liquidity.
What makes Quantum-Si unique
- Quantum-Si’s Proteus chip integrates sequencing chemistry, KinetIQ Array, and software into one workflow.
- On April 28, 2026, Proteus achieved automated sequencing on integrated instruments without user intervention.
- Jonathan Rothberg’s DNA-sequencing pedigree gives Quantum-Si rare credibility in benchtop life-sciences tools.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Real-time performance monitoring
Remote Work Options
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 1%2 year growth
↑ 3%Quantum-Si has delayed the launch of its Proteus proteomics platform from late 2026 to Q2 2027 to incorporate an additional design cycle focused on manufacturing risk reduction and system repeatability. Internal testing revealed that proceeding directly to production would carry unacceptable execution risk. The company announced a 20% workforce reduction expected to save $12 million annually in operating expenses. This aligns costs with the extended development timeline whilst preserving core Proteus work streams. Cash runway now extends into Q4 2028. Management raised the amino acid detection target at launch to 19 or 20, up from 18 previously. The company is also shifting its library preparation strategy to application-oriented kits rather than a single generic kit. Full-year 2026 guidance remains unchanged, with revenue expected at approximately $1 million and adjusted operating expenses capped at $98 million.
Quantum-Si has delayed the launch of its Proteus protein sequencing platform to the second quarter of 2027 from the end of 2026, citing the need for an additional integrated instrument design cycle before production. The company is also cutting its workforce by approximately 20% to reduce cash burn and fund the revised development timeline. Chief Executive Officer Jeff Hawkins said the delay stems from an internal review of instrument performance, manufacturing processes, and supply-chain readiness. Testing of integrated units during the first half of 2026 revealed variability in performance across systems. Some instruments performed above internal specifications, while others met or fell slightly below targets. The additional design cycle will focus on improving repeatability across systems and making manufacturing changes to simplify production and improve yields.
Quantum-Si has delayed the commercial launch of its Proteus protein sequencing platform to Q2 2027 and implemented a 20% workforce reduction to extend its cash runway into Q4 2028. The proteomics technology company reported second quarter revenue of $344,000, down from $591,000 in the prior year period. The company posted a net loss of $23.5 million for the quarter, compared to $28.8 million a year earlier. The launch delay incorporates an additional design cycle focused on manufacturing readiness and system repeatability. Chief executive Jeff Hawkins said testing has reinforced confidence in the technology, whilst the extra cycle will strengthen commercialisation readiness. Quantum-Si highlighted a $4 billion annual market opportunity in non-human proteomics, identified through work on agricultural applications and pathogen detection. The workforce reduction is expected to generate approximately $12 million in annualised savings whilst maintaining critical development resources.
Quantum-Si (NASDAQ:QSI) announces quarterly earnings results. August 13, 2026 Key points. * Quantum-Si met earnings expectations, reporting a quarterly loss of $0.11 per share, while revenue of $0.34 million exceeded analysts' $0.30 million forecast. The company continued to report significant net losses and negative return on equity. * Shares fell to $0.79, near the lower end of their 52-week range of $0.69 to $3.10. Analysts maintain a consensus "Reduce" rating with a $1.00 price target, while Weiss Ratings downgraded the stock to "sell (e+)." * Institutional ownership stands at 39.90%, with investors including Millennium Management, State Street, Bank of America and Geode Capital increasing or initiating positions in Quantum-Si. * MarketBeat previews the top five stocks to own by September 1st. Quantum-Si (NASDAQ:QSI - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.11) EPS for the quarter, hitting analysts' consensus estimates of ($0.11), FiscalAI reports. The business had revenue of $0.34 million for the quarter, compared to analysts' expectations of $0.30 million. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 47.35%. Quantum-Si price performance. NASDAQ QSI traded down $0.05 during trading hours on Thursday, reaching $0.79. The company's stock had a trading volume of 4,129,465 shares, compared to its average volume of 4,733,177. The firm has a market capitalization of $172.03 million, a price-to-earnings ratio of -1.55 and a beta of 3.24. The company's 50-day moving average is $0.88 and its two-hundred day moving average is $0.93. Quantum-Si has a 1-year low of $0.69 and a 1-year high of $3.10. Wall Street analyst weigh in. Separately, Weiss Ratings cut shares of Quantum-Si from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus price target of $1.00. Institutional inflows and outflows. Several large investors have recently made changes to their positions in QSI. Millennium Management LLC acquired a new stake in shares of Quantum-Si in the first quarter valued at about $4,721,000. State Street Corp boosted its holdings in Quantum-Si by 26.5% in the 4th quarter. State Street Corp now owns 3,562,721 shares of the company's stock worth $3,919,000 after buying an additional 745,231 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Quantum-Si in the 3rd quarter worth about $865,000. Bank of America Corp DE increased its stake in Quantum-Si by 426.6% during the 2nd quarter. Bank of America Corp DE now owns 465,999 shares of the company's stock worth $913,000 after buying an additional 377,504 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Quantum-Si by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 4,114,375 shares of the company's stock worth $4,527,000 after buying an additional 367,206 shares in the last quarter. 39.90% of the stock is owned by institutional investors and hedge funds. Quantum-Si company profile. Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company's core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods. Quantum-Si's product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Quantum-Si, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum-Si wasn't on the list. While Quantum-Si currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Quantum-Si reported first-quarter 2026 revenue of $258,000 and said the year would focus on development and market preparation for its next-generation Proteus protein sequencing platform, which is expected to launch commercially by year-end. The company completed sequencing on fully integrated Proteus instruments during the quarter, a milestone CEO Jeff Hawkins described as a significant de-risking event. Quantum-Si increased detectable amino acids from 15 to 17 within four months and aims to detect 18 amino acids at launch and all 20 during 2026. Proteus is expected to offer advantages over the current Platinum system, including automation, higher throughput and longer peptide read lengths. The company is also developing post-translational modification analysis capabilities for the platform.